electroCore, Inc. (NASDAQ:ECOR – Free Report) – Stock analysts at HC Wainwright upped their FY2028 earnings per share estimates for electroCore in a report released on Thursday, March 13th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of $2.25 per share for the year, up from their prior estimate of $2.24. HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for electroCore’s current full-year earnings is ($1.49) per share. HC Wainwright also issued estimates for electroCore’s FY2029 earnings at $3.07 EPS.
Separately, LADENBURG THALM/SH SH lowered their target price on electroCore from $28.00 to $26.00 and set a “buy” rating for the company in a research note on Thursday.
electroCore Price Performance
ECOR opened at $8.56 on Friday. electroCore has a 12 month low of $5.32 and a 12 month high of $19.49. The stock has a market capitalization of $56.98 million, a price-to-earnings ratio of -4.68 and a beta of 0.24. The business has a fifty day moving average price of $15.84 and a 200 day moving average price of $12.31.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC lifted its holdings in electroCore by 10.3% during the 3rd quarter. Geode Capital Management LLC now owns 63,485 shares of the company’s stock worth $458,000 after buying an additional 5,951 shares during the last quarter. HighTower Advisors LLC purchased a new stake in electroCore during the 3rd quarter worth about $255,000. Jane Street Group LLC purchased a new stake in electroCore during the 4th quarter worth about $278,000. JPMorgan Chase & Co. lifted its holdings in electroCore by 31,250.0% during the 4th quarter. JPMorgan Chase & Co. now owns 3,762 shares of the company’s stock worth $61,000 after buying an additional 3,750 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in electroCore during the 4th quarter worth about $438,000. 26.74% of the stock is owned by institutional investors and hedge funds.
electroCore Company Profile
electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
Recommended Stories
- Five stocks we like better than electroCore
- ESG Stocks, What Investors Should Know
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What Are Growth Stocks and Investing in Them
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.